The viral story of the day isn't another model release — it's a generative AI company building a full-body scanner. Midjourney CEO David Holz unveiled Midjourney Medical, a project the company is framing as one of the most ambitious bets in consumer health hardware in a generation.
Holz revealed what he described as a "full-body ultrasound machine" called the Midjourney Scanner, claiming "no such device has ever been built until now" and touting it as superior to MRI in numerous ways. The device is paired with a consumer-facing concept called the Midjourney Spa — a 60-second whole-body scan framed as casual as a trip to the spa.
The numbers behind the ambition are eye-watering. Where traditional MRI scans cost between $400 and $4,000 and take upwards of two hours, Midjourney claims its scanner executes a full-body scan in 60 seconds — and Holz claimed fewer than a dozen of these machines operating concurrently could process more full-body scans than every active MRI machine on Earth combined. The company is targeting 50,000 scanners globally by 2031, with a combined capacity of one billion sessions per month.
The disruptive potential is powerful: an AI lab just pivoted from pixels to the actual foundations of human longevity.
Why This Validates the Longevity Trade
Midjourney's own pitch: with enough early imaging, the world could avoid 30% of all deaths and 50% of all healthcare costs. Whether or not that number holds, the strategic message to investors is unmistakable — the smartest AI operators now believe the highest-value use of intelligence is keeping humans alive longer. That is the exact thesis underpinning our longevity & wellness book.
AI firms and policymakers increasingly view health and longevity as AI's most valuable long-term application, and Midjourney's scanner targets the data-collection layer — frequent, accessible full-body imaging that feeds the longitudinal health datasets AI models need to detect change over time, not just deliver a single diagnostic snapshot. Every public company in our basket sits somewhere on that data pipeline.
How the Public Names Stack Up
The direct-to-consumer telehealth leader in our basket is the most direct consumer-behavior beneficiary of the "proactive, frequent health decisions" worldview Midjourney just amplified. LikeFolio's Main Street Score of 69 confirms what we've been seeing in consumer data — demand for self-directed health and wellness is structural, not a fad. Our composite LikeFolio Score sits at 75, and this name is an open position in our Core Conviction playbook. The weekly tape has been ugly, but the multi-year setup just got a fresh narrative tailwind.
The AI-driven precision medicine platform on our list is arguably the closest publicly traded analog to what Midjourney is trying to build — an AI platform sitting on top of multimodal patient data. The company just launched a digital pathology open-source consortium with Yale New Haven Hospital and Memorial Sloan Kettering, and an expanded Bristol Myers Squibb collaboration now puts its platform at the center of five oncology and neuroscience clinical programs. Our composite LikeFolio Score is 66 — the strategic relevance of this name went up materially today.
The AI-enabled drug discovery name is the speculative arm of the trade — AI applied to drug discovery rather than imaging. The company just presented at the Goldman Sachs 47th Annual Global Healthcare Conference and highlighted progress on its AI-enabled drug discovery platform alongside clinical updates for two lead programs, with FDA feedback on the regulatory path for one of them now in focus. Cash sat at $665.2M at the end of Q1, with runway guided into early 2028 — meaningful dilution risk is off the table. Our LikeFolio Score of 64 frames this as the cheap optionality piece of the basket.
The genetic testing and oncology diagnostics leader rounds out the data layer. The company reported Q1 2026 revenue of $696.6 million, up 38.8% year-over-year, processed over 1 million tests in a single quarter for the first time, saw oncology revenue grow 54.4%, and lifted full-year 2026 revenue guidance to $2.74–$2.82 billion. Our composite LikeFolio Score is 66. The fundamentals are running hot — the question is whether current levels already reflect it.
The Bigger Picture
Midjourney's pivot is a tell. When a generative AI lab with no investors and unlimited optionality chooses preventative health imaging as its next product, it's broadcasting where the smartest capital sees the largest unsolved markets. As Holz himself argued, the scanner is a new pillar of AI-enabled healthcare — AI needs fast, rich, cheap bodily data, and the future is about infrastructure that lets AI reason over the physical body.
We'll be tracking pin action plays that emerge from here...
Pro subscribers get the full breakdown — specific tickers, directional calls, entry levels, and price targets across all four names in our longevity basket. Upgrade to unlock the complete playbook.